Soley Bayraktar1, Laura Amendola2, Angelica M Gutierrez-Barrera1, Syed S Hashmi3, Chris Amos4, Michael Gambello5, Kaylene J Ready6, Banu Arun7. 1. Departments of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States. 2. Division of Medical Genetics, University of Washington Medical Center, United States. 3. Biostatistics, The University of Texas School of Public Health, Houston, TX, United States. 4. Clinical Cancer Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. 5. Division of Medical Genetics, Department of Pediatrics, The University of Houston Medical School, Houston, TX, United States. 6. Division of Clinical Cancer Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. 7. Departments of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States; Division of Clinical Cancer Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. Electronic address: barun@mdanderson.org.
Abstract
PURPOSE: Breast cancer diagnosed in women 35 years of age or less accounts for <2% of all breast cancer cases. Clinical and pathologic characteristics of early onset breast cancer are not well defined in BRCA mutation carriers and non-carriers. METHODS: 194 women diagnosed with breast cancer at 35 years of age or less who had BRCA1/2 mutation testing were included in the study. Logistic regression models were fit to determine the associations between clinical variables and BRCA status. RESULTS: Thirty-two (17%) and 12 (6%) patients had BRCA1 and BRCA2 mutations, respectively. BRCA1-carriers had a higher likelihood of a positive family history (FH) of breast and/or ovarian cancer (P = 0.001), or first-degree relatives diagnosed with breast cancer at <50 years old (P = 0.001) compared to non-carriers. BRCA2-carriers were more likely to have a FH of male breast cancer compared to noncarriers (P = 0.02). Among BRCA2-carriers, the age at first full-term pregnancy was younger in ER-negative cases compared with ERpositive cases (19.5 vs. 28.5 years old; P = 0.01). BRCA1-carriers with a later age at menarche were more likely to have a later stage at diagnosis (P = 0.04). Non-carriers with a lower BMI were more likely to have lymph node involvement (P = 0.03). CONCLUSIONS: Several associations were identified between reproductive risk factors or BMI and disease characteristics. Further characterization may result in a better understanding of the trends in young onset breast cancer in BRCA-carriers and non-carriers.
PURPOSE:Breast cancer diagnosed in women 35 years of age or less accounts for <2% of all breast cancer cases. Clinical and pathologic characteristics of early onset breast cancer are not well defined in BRCA mutation carriers and non-carriers. METHODS: 194 women diagnosed with breast cancer at 35 years of age or less who had BRCA1/2 mutation testing were included in the study. Logistic regression models were fit to determine the associations between clinical variables and BRCA status. RESULTS: Thirty-two (17%) and 12 (6%) patients had BRCA1 and BRCA2 mutations, respectively. BRCA1-carriers had a higher likelihood of a positive family history (FH) of breast and/or ovarian cancer (P = 0.001), or first-degree relatives diagnosed with breast cancer at <50 years old (P = 0.001) compared to non-carriers. BRCA2-carriers were more likely to have a FH of male breast cancer compared to noncarriers (P = 0.02). Among BRCA2-carriers, the age at first full-term pregnancy was younger in ER-negative cases compared with ERpositive cases (19.5 vs. 28.5 years old; P = 0.01). BRCA1-carriers with a later age at menarche were more likely to have a later stage at diagnosis (P = 0.04). Non-carriers with a lower BMI were more likely to have lymph node involvement (P = 0.03). CONCLUSIONS: Several associations were identified between reproductive risk factors or BMI and disease characteristics. Further characterization may result in a better understanding of the trends in young onset breast cancer in BRCA-carriers and non-carriers.
Authors: D Ribnikar; J M Ribeiro; D Pinto; B Sousa; A C Pinto; E Gomes; E C Moser; M J Cardoso; F Cardoso Journal: Curr Treat Options Oncol Date: 2015-04
Authors: Li-Chen Tang; Xi Jin; Hai-Yuan Yang; Min He; Helena Chang; Zhi-Ming Shao; Gen-Hong Di Journal: BMC Cancer Date: 2015-03-29 Impact factor: 4.430